InsidersTradesSigma
Total declarations
Company
▲ Purchases (17 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
17
Disclosed sells
0
T+90 hit rate
17%
T+90 mean return
-14.7%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Wong Hing C. Director active across 1 company, notably HCW Biologics Inc.. Cumulatively, 20 filings have been published. Split: 17 buys · 0 sell. Total volume traded: €2.4m. History available since 22 July 2021. The latest transaction was filed on 16 May 2025 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations20 total
8,054 shares@ US$7.451.6% of flowCommon StockSEC:0000950170-25-075259:0
Ideal exit: 10 Feb 2026 (T+270)
92,500 shares@ US$26.0064.0% of flowCommon StockSEC:0000950170-25-068292:0
Ideal exit: 2 Feb 2026 (T+270)
739,288 shares@ US$1.4028.7% of flowCommon StockSEC:0001209191-24-003787:0
1,800 shares@ US$2.07821.8% of flowCommon StockSEC:0001209191-23-049774:0
Ideal exit: 10 Jun 2024 (T+270)
800 shares@ US$1.61780.0% of flowCommon StockSEC:0001209191-23-034098:0
Ideal exit: 26 Feb 2024 (T+270)
3,000 shares@ US$1.55270.1% of flowCommon StockSEC:0001209191-23-033397:0
Ideal exit: 24 Feb 2024 (T+270)
4,000 shares@ US$2.670.3% of flowCommon StockSEC:0001209191-22-049469:0
Ideal exit: 5 Jun 2023 (T+270)
4,000 shares@ US$2.550.3% of flowCommon StockSEC:0001209191-22-049055:0
Ideal exit: 30 May 2023 (T+270)
1,520 shares@ US$2.1880.038% mcap1.9% of flowCommon StockSEC:0001209191-22-036395:0
Ideal exit: 7 Mar 2023 (T+270)
1,000 shares@ US$2.310.026% mcap1.3% of flowCommon StockSEC:0001209191-22-035554:0
Ideal exit: 4 Mar 2023 (T+270)
5,830 shares@ US$3.940.24% mcap11.9% of flowCommon StockSEC:0001209191-21-059989:0
Ideal exit: 28 May 2022 (T+270)
8,000 shares@ US$3.76250.31% mcap15.7% of flowCommon StockSEC:0001209191-21-059988:0
Ideal exit: 24 May 2022 (T+270)
5,830 shares@ US$3.940.6% of flowCommon StockSEC:0001209191-21-059989
Ideal exit: 28 May 2022 (T+270)
8,000 shares@ US$3.76250.8% of flowCommon StockSEC:0001209191-21-059988
Ideal exit: 24 May 2022 (T+270)
3,830 shares@ US$3.93480.4% of flowCommon StockSEC:0001209191-21-054545
Ideal exit: 28 May 2022 (T+270)
3,830 shares@ US$3.93480.16% mcap7.8% of flowCommon StockSEC:0001209191-21-054545:0
Ideal exit: 28 May 2022 (T+270)
6,500 shares@ US$3.84150.6% of flowCommon StockSEC:0001209191-21-053958
Ideal exit: 23 May 2022 (T+270)
6,500 shares@ US$3.84150.26% mcap13.0% of flowCommon StockSEC:0001209191-21-053958:0
Ideal exit: 23 May 2022 (T+270)
6,316,691 shares0Common StockSEC:0001209191-21-048063
6,316,691 shares0Common StockSEC:0001209191-21-048063:0
20 of 20 declarations
About Wong Hing C
Wong Hing C is a director at HCW Biologics Inc.
